Aliko Scientific: Financial Status and Outlook

On August 24, 2026, Aliko Scientific released financial information following its 2025 annual results. The company, specializing in oncology diagnostics, detailed its financial strategy, which includes convertible bond issuances and optimized liability management. These initiatives aimed to strengthen its financial position and secure funding for the next twelve months.

The auditors' reports highlighted some uncertainty regarding the company's ability to continue as a going concern, although without any major reservations. Despite total debt of €5.74 million at the beginning of 2026, a significant reduction is expected. Furthermore, industrial and commercial development, particularly with the Urine24 product and several distribution agreements, is progressing. Management remains optimistic about maintaining growth.